Clinical Research Directory
Browse clinical research sites, groups, and studies.
Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy
Sponsor: First Affiliated Hospital, Sun Yat-Sen University
Summary
The goal of this trial is to test whether patients with stage III papillary renal cell carcinoma (pRCC) could benefit from adjuvant therapy or not. The investigators invented a multi-classifier system that was successfully categorise patients with stage III pRCC into high-risk and low-risk groups. Here the investigators randomly assign classifier-defined high risk patients of stage III pRCC into adjuvant pembrolizumab group placebo group. Disease-free survival and overall survival are the end points of observation.
Official title: A Multicenter, Open, Prospective Study of Prognostic Value and Benefit From Adjuvant Immunotherapy of Stage III Papillary Renal Cell Carcinoma Based on Multi-classifier System
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
468
Start Date
2023-12-01
Completion Date
2030-12-01
Last Updated
2023-11-29
Healthy Volunteers
No
Conditions
Interventions
Pembrolizumab
Intravenous infusion
Placebo
Intravenous infusion